Joseph Bertino
Overview
Explore the profile of Joseph Bertino including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
265
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shen M, Wei Y, Kim H, Wan L, Jiang Y, Hang X, et al.
Nat Cancer
. 2022 Feb;
3(1):43-59.
PMID: 35121987
Metastatic breast cancer is a leading health burden worldwide. Previous studies have shown that metadherin (MTDH) promotes breast cancer initiation, metastasis and therapy resistance; however, the therapeutic potential of targeting...
2.
Allen J, Kline C, Prabhu V, Wagner J, Ishizawa J, Madhukar N, et al.
Oncotarget
. 2021 Oct;
12(21):2231.
PMID: 34676056
[This corrects the article DOI: 10.18632/oncotarget.11814.].
3.
4.
Shields S, Lesandrini J, Bertino J
J Physician Assist Educ
. 2019 Oct;
30(4):236-238.
PMID: 31664006
No abstract available.
5.
Glover A, Bertino J
J Physician Assist Educ
. 2018 Nov;
29(4):247-250.
PMID: 30461590
No abstract available.
6.
Yu X, Kogan S, Chen Y, Tsang A, Withers T, Lin H, et al.
Clin Cancer Res
. 2018 Jun;
24(18):4505-4517.
PMID: 29914895
Zinc metallochaperones (ZMC) are a new class of anticancer drugs that reactivate zinc-deficient mutant p53 by raising and buffering intracellular zinc levels sufficiently to restore zinc binding. pharmacodynamics of ZMCs...
7.
Wagner J, Kline C, Zhou L, Campbell K, Macfarlane A, Olszanski A, et al.
J Clin Invest
. 2018 Mar;
128(6):2325-2338.
PMID: 29533922
ONC201 is a first-in-class, orally active antitumor agent that upregulates cytotoxic TRAIL pathway signaling in cancer cells. ONC201 has demonstrated safety and preliminary efficacy in a first-in-human trial in which...
8.
Allen J, Kline C, Prabhu V, Wagner J, Ishizawa J, Madhukar N, et al.
Oncotarget
. 2016 Sep;
7(45):74380-74392.
PMID: 27602582
ONC201 is the founding member of a novel class of anti-cancer compounds called imipridones that is currently in Phase II clinical trials in multiple advanced cancers. Since the discovery of...
9.
Tefferi A, Kantarjian H, Rajkumar S, Baker L, Abkowitz J, Adamson J, et al.
Mayo Clin Proc
. 2015 Jul;
90(8):996-1000.
PMID: 26211600
No abstract available.
10.
Budak-Alpdogan T, Przybylowski M, Gonen M, Sadelain M, Bertino J, Riviere I
Hum Gene Ther
. 2006 Jul;
17(7):780-94.
PMID: 16839276
The successful transduction and engraftment of human mobilized peripheral blood (MBP) CD34(+) cells are determined to a large extent by the ex vivo cell-processing conditions. In preparation for upcoming clinical...